These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 9096267)
21. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging. Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354 [TBL] [Abstract][Full Text] [Related]
22. The diagnostic value of urinary Crosslaps and serum alkaline phosphatase in patients with prostate cancer. Nguyen-Pamart M; Caty A; Feutrie ML; Fournier C; Gosselin P; Mazeman E Br J Urol; 1997 Sep; 80(3):452-5. PubMed ID: 9313666 [TBL] [Abstract][Full Text] [Related]
23. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio. Kaynar M; Yildirim ME; Gul M; Kilic O; Ceylan K; Goktas S Cancer Biomark; 2015; 15(3):317-23. PubMed ID: 25586096 [TBL] [Abstract][Full Text] [Related]
24. The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer. Fosså SD; Waehre H; Paus E Br J Cancer; 1992 Jul; 66(1):181-4. PubMed ID: 1379059 [TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of skeletal AP and PSA with respect to skeletal scintigram in patients with prostatic disease. Oremek GM; Kramer W; Seiffert UB; Jonas D Anticancer Res; 1997; 17(4B):3035-6. PubMed ID: 9329594 [TBL] [Abstract][Full Text] [Related]
26. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma. Klepzig M; Jonas D; Oremek GM Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219 [TBL] [Abstract][Full Text] [Related]
27. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer? Tarle M; Kraljić I Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191 [TBL] [Abstract][Full Text] [Related]
28. Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression. Wu T; Kasper S; Wong RM; Bracken B Clin Genitourin Cancer; 2020 Apr; 18(2):e174-e179. PubMed ID: 31899150 [TBL] [Abstract][Full Text] [Related]
29. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase. Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186 [TBL] [Abstract][Full Text] [Related]
30. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group]. Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478 [TBL] [Abstract][Full Text] [Related]
31. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Yoshida K; Sumi S; Arai K; Koga F; Umeda H; Hosoya Y; Honda M; Yano M; Moriguchi H; Kitahara S Cancer; 1997 Nov; 80(9):1760-7. PubMed ID: 9351545 [TBL] [Abstract][Full Text] [Related]
32. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. Xie W; Nakabayashi M; Regan MM; Oh WK Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608 [TBL] [Abstract][Full Text] [Related]
33. Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study. Dwivedi S; Goel A; Natu SM; Mandhani A; Khattri S; Pant KK Asian Pac J Cancer Prev; 2011; 12(7):1843-8. PubMed ID: 22126577 [TBL] [Abstract][Full Text] [Related]
34. Survival markers related to bone metastases in prostate cancer. Salminen EK; Kallioinen MJ; Ala-Houhala MA; Vihinen PP; Tiitinen SL; Varpula M; Vahlberg TJ Anticancer Res; 2006; 26(6C):4879-84. PubMed ID: 17214355 [TBL] [Abstract][Full Text] [Related]
35. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. Morote J; Lorente JA; Encabo G Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009 [TBL] [Abstract][Full Text] [Related]
37. [Significance of the PSA-concentration for the detection of prostate cancer]. Stachon A Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861 [TBL] [Abstract][Full Text] [Related]
38. [Biomarkers of prostate cancer and potential for using ace produced in prostate gland for diagnosis of prostate cancer and benign prostatic hyperplasia]. Kamalov AA; Samokhodskaya LM; Karpov VK; Okhobotov DA; Mamedov VN Urologiia; 2019 Jun; (2):73-81. PubMed ID: 31162906 [TBL] [Abstract][Full Text] [Related]